Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
GAITHERSBURG, Md., Sept. 07, 2016 -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived audio of the presentation will also be available on OpGen’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contacts:
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
[email protected]
[email protected]
Investor Relations
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]
Bruce Voss
(310) 691-7100
[email protected]
OpGen Media
MacDougall Biomedical Communications
Cammy Duong
(781) 235-3060
[email protected]
